Analyst Ratings January 29, 2026

H.C. Wainwright Reaffirms Buy on Halozyme After Company Raises FY25 Guidance

Analyst keeps $90 price target as Halozyme tightens royalty visibility and records continued deal activity for ENHANZE

By Marcus Reed HALO
H.C. Wainwright Reaffirms Buy on Halozyme After Company Raises FY25 Guidance
HALO

H.C. Wainwright reiterated a Buy rating and maintained a $90 per share 12-month price target on Halozyme Therapeutics (NASDAQ: HALO) after the company raised its FY25 revenue guidance and narrowed royalty revenue expectations. The analyst firm cited stronger visibility into ENHANZE royalty streams and recent business development activity as supporting the platform's durability. Halozyme also provided multi-year revenue projections and announced collaborations and regulatory progress tied to its ENHANZE drug delivery technology.

Key Points

  • H.C. Wainwright reiterated a Buy rating on Halozyme and maintained a $90 per share 12-month price target after updating its forecasts to match Halozyme's guidance.
  • Halozyme raised FY25 total revenue guidance to $1.385-1.40 billion and narrowed FY25 royalty revenue guidance to $865-870 million, citing upfront milestones from Merus and Takeda alongside stronger product sales.
  • The company provided multi-year revenue projections for 2026-2028 and announced collaborations with Takeda and Skye Bioscience; the FDA also approved RYBREVANT FASPRO as a subcutaneous targeted therapy for EGFR-mutated non-small cell lung cancer.

H.C. Wainwright has reaffirmed its Buy rating on Halozyme Therapeutics (NASDAQ: HALO) and kept a 12-month price target of $90 per share, according to a research note published Thursday. The research firm adjusted its forward estimates to reflect Halozyme's recently updated guidance.

Halozyme raised its full-year FY25 total revenue guidance to a range of $1.385 billion to $1.40 billion, above its earlier forecast. The company attributed this upward revision to upfront milestone payments from Merus and Takeda, which were signed in December 2025, together with stronger product sales. Over the trailing twelve months Halozyme reported revenue growth of 31.19%, generating $1.24 billion in revenue during that period.

In addition to the broader revenue increase, Halozyme narrowed its FY25 royalty revenue guidance to $865 million to $870 million, down from a prior range of $850 million to $880 million. H.C. Wainwright noted that the tightened royalty range reflects improved visibility into expected royalties rather than signaling a change in underlying demand assumptions.

The research note emphasized January business development activity as an important factor for investors, saying recent deals removed a key concern about the long-term viability of partnerships built around Halozyme's ENHANZE platform. The firm described the combined effect of the raised revenue guidance, clearer royalty visibility, and continued deal momentum as reinforcing ENHANZE's position as a "durable, non-commodity platform."

H.C. Wainwright left its 12-month price target unchanged at $90 while updating its estimates to align with Halozyme's new guidance ranges.


Separately, Halozyme issued revenue guidance for the coming years, projecting $1.71 billion to $1.81 billion for 2026, $1.92 billion to $2.05 billion for 2027, and $2.05 billion to $2.17 billion for 2028. Those multi-year figures were noted as exceeding consensus estimates and tracking closely with projections from Goldman Sachs, except for 2028 where Goldman Sachs' estimate is slightly higher. Goldman Sachs has maintained a Sell rating on Halozyme with a $58 price target.

Corporate developments tied to ENHANZE featured in the update. Halozyme entered a global collaboration and exclusive license agreement with Takeda for use of its ENHANZE drug delivery technology with vedolizumab. The company also signed a non-exclusive global collaboration with Skye Bioscience to develop a subcutaneous formulation of the obesity drug nimacimab, allowing Skye to use ENHANZE to evaluate higher dose levels.

On the regulatory front, the FDA approved Halozyme's RYBREVANT FASPRO for the treatment of EGFR-mutated non-small cell lung cancer. That approval was highlighted as the first subcutaneously administered targeted therapy for this indication to incorporate ENHANZE technology.

The combination of upgraded near-term revenue guidance, tightened royalty estimates, continued collaboration activity, and regulatory progress formed the backbone of H.C. Wainwright's maintained positive stance on the stock.

Risks

  • Ongoing reliance on ENHANZE partnerships - investor concerns about the long-term viability of those collaborations were noted as an issue prior to recent business development activity; this affects expectations in the biotech and pharmaceutical sectors.
  • Royalty revenue variability - although FY25 royalty guidance was narrowed to reflect improved visibility, changes in royalty receipts could affect Halozyme's revenue profile and investor sentiment in healthcare and biotech markets.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026